|
|
Volumn 42 Suppl 2, Issue , 2003, Pages
|
|
Combined modality therapy for non-small cell lung cancer, past, present, and future.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYCLOOXYGENASE 2;
ENZYME INHIBITOR;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ISOENZYME;
MEMBRANE PROTEIN;
PROSTAGLANDIN SYNTHASE;
PTGS2 PROTEIN, HUMAN;
DRUG ANTAGONISM;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
MULTIMODALITY CANCER THERAPY;
PROGNOSIS;
REVIEW;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
COMBINED MODALITY THERAPY;
CYCLOOXYGENASE 2;
ENZYME INHIBITORS;
HUMANS;
ISOENZYMES;
LUNG NEOPLASMS;
MEMBRANE PROTEINS;
PROGNOSIS;
PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
MLCS;
MLOWN;
|
|
EID: 17144436630
PISSN: 01695002
EISSN: None
Source Type: Journal
DOI: 10.1016/j.lungcan.2003.08.009 Document Type: Review |
|
Times cited : (4)
|
|
References (40)
|
